From the pharmacy of the world to your tender desk.
M Care is an Indian-owned pharmaceutical export house supplying WHO-GMP and EU-GMP medicines, biologicals and surgical consumables to hospitals, importers and government tender desks across the United Kingdom, the GCC, and Africa, with destination-ready dossiers, validated cold-chain, and a single named account manager on every shipment.
Our supply-integrity promise.
For a buyer who has never met us, the real question is not the price. It is whether the box is what the label says. This is the chain we hold on every single line we ship.
Manufacturer-direct
Every line is sourced straight from a WHO-GMP manufacturer against your purchase order. We are not a broker, we hold no speculative stock, and we do not buy on the grey market.
Documented end to end
A batch Certificate of Analysis, the WHO-format CoPP, the manufacturer's GMP certificate and the cold-chain trail travel with the consignment, prepared to your destination regulator's expectation.
To your licensed entity
We supply the WHO-GMP product; the importer of record is your own licensed local entity. One named desk carries the order from purchase order to the signature on the delivery note.
Rooted in the world's pharmacy
India supplies ~60% of the world's vaccines and the largest share of quality-assured generics outside the US. That is the manufacturing base we buy against, then QA, dossier and ship on your behalf.
Regulator-ready, destination-first
CTD/eCTD dossiers written for MHRA, EMA, SFDA, MoH-UAE, NAFDAC and the rest of the regulators we ship into, not a generic template repurposed page-by-page.
One named person on every order
No call-centre triage, no vanishing reply chains. Your Mumbai desk knows your molecule, your market, your pack-size preference and your customs broker by name.
Six specialty services. One operational backbone.
Sourcing, regulatory affairs, cold-chain logistics and post-shipment aftercare run through the same team in Mumbai. The number on day-one's quote is the number on day-forty's invoice.
Cold-chain validation
Validated 2–8°C and −25°C lanes for vaccines, insulins, biologics. Live telemetry. CAPA opened pre-dispatch.
Cold-chain protocol →Orphan drug supply
Rare-disease medicines into MHRA EAMS, EU compassionate-use and global named-patient access. Single-batch supportable.
Orphan drug route →Government supply services
End-to-end tender response: NUPCO, MoHAP, NHS framework, KEMSA, EPSS and donor-funded pooled procurement. 48+ countries.
Government tenders →Comparator drugs & clinical trials supply
CRO-side comparator sourcing for Phase 2/3 trials. GCP-aligned, EU CTR / FDA IND ready, blind-packaging supported.
Comparator drugs & IMPs →A network across forty-nine markets, anchored in three desks.
Three desks. Forty-six destinations. One signal across the network. Browse all markets →
Eight markets, three continents, one Mumbai desk.
NHS Specials in the UK, BfArM-recognised imports into Germany, GCC ministry-of-health tenders, NAFDAC Nigeria and SAHPRA South Africa. Live regulator dossiers, validated cold-chain lanes from Mumbai, and named procurement bodies on every card.
Depth where you need it. Breadth where you don't.
Eighteen therapeutic categories, 165,000+ SKU portfolio, every line traceable to a named WHO-GMP or EU-GMP manufacturing site.
Three recent shipment patterns.
UK Specials, docetaxel shortage window. Reg. 167 named-patient consignment closed the licensed-source gap in 11 days end-to-end. Document pack pre-built; cold-chain on the BOM-LHR lane.
Gulf hospital, biological cold-chain. Active-shipper consignment, 72-hour BOM-DXB lane. Continuous IoT logging in transit. Logger record: zero excursions outside the 2-8°C band.
NUPCO central tender response. 18-day biosimilar tender window. CTD dossier harmonised to GHC central format; SFDA stability appendix; Arabic-language SmPC. Response went on day 14.
Also documented across the African lane: KEMSA Kenya anti-infective framework supply (2024), Tanzania MSD ARV catalogue dispatch under the WHO PQ collaborative procedure (2025, 11-week time-to-first-dispatch versus an 18-month standard registration cycle), NAFDAC Nigeria verification-track filings for haematology biosimilars (2024), FDA Ghana ICUMS-portal lodgement for a Christian Health Association of Ghana (CHAG) wholesaler partner (2025).
Buyer references available against signed mutual NDA. Direct introduction facilitated where a prospective buyer's diligence requires a peer reference.
Practical notes from the regulatory and tender lanes we run.
Incoterms and payment terms for pharma imports
Where risk and cost transfer (and why DDP rarely fits regulated medicine), plus the payment instrument that protects both sides: advance, Letter of Credit, D/P, D/A.
Read note → Nigeria · NAFDACNAFDAC drug registration in Nigeria
The two gates every medicine clears: one-time NAFDAC product registration and per-shipment Form M / PAAR import clearance, with realistic timelines.
Read note → Buyer · Due diligenceHow to verify a pharmaceutical exporter in India
The documents to demand and the public registers that confirm each one: WHO-GMP, CoPP, CTD, IEC. A buyer's due-diligence workflow before the first order.
Read note →Tell us which molecule, which market, which volume.
One working day to a written reply with price, availability and regulatory status for your destination. No call-centre triage. No sales funnel. Just a human in Mumbai with the answer.
Request a quote → Request data package Browse portfolio